The Relationship Between APOE Genotype And SAH And An ApoE-mimetic Peptide Therapeutic Reduces Vasospasm And Improves Outcome In A Murine Model Of SAH

Objectives: Subarachnoid hemorrhage (SAH) is one of the commonnest cerebral emergency diseases. Its mortality is highly up to 40%-60%. Vasospasm is the most serious complication of SAH. Clinical management of vasospasm has progressed slowly over the past several decades and remains ineffective in a large number of patients. To gain new insights into this complex disease, the application of advances in vasospasm animal model technology may be of value. Several animal models of vasospasm have been described, each offering specific advantages. Measurement of vasospasm is challenging in mice simply because of the size of the vasculature. Our goal was to characterize a mouse model of SAH and delayed cerebral vasospasm.Several recent clinical studies have documented an association between the APOE4 allele and the poor outcome after subarachnoid hemorrhage (SAH). Despite an advances in early diagnosis and management, SAH remains a frequent cause of death and disability. In particular, vasospasm is one of the most feared medical complications of subarachnoid hemorrhage, and often leads to delayed ischemic deficit and stroke. A recent study demonstrated that the presence of the APOE4 allele was associated both with an increased incidence of delayed ischemic deficit, and worsen prognosis in this subgroup of patients.Therapeutic interventions to prevent and treat this complication remain limited. Thus, a better understanding of the role that endogenous proteins such as apoE playing in the brain after acute injury may allow the development of novel apoE-based therapies. Moreover, administration of an apoE-based therapeutic has been demonstrated to improve the outcomes in a clinically...